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Background: The anti-inflammatory effect of the cerebral dopamine neurotrophic factor (CDNF) was shown recently
in primary glial cell cultures, yet such effect remains unknown both in vivo and in 6-hydroxydopamine (6-OHDA)
models of Parkinson? s disease (PD). We addressed this issue by performing an intranigral transfection of the human
CDNF (hCDNF) gene in the critical period of inflammation after a single intrastriatal 6-OHDA injection in the rat.
Methods: At day 15 after lesion, the plasmids p3xNBRE-hCDNF or p3xNBRE-EGFP, coding for enhanced green
florescent protein (EGFP), were transfected into the rat substantia nigra (SN) using neurotensin (NTS)-polyplex. At
day 15 post-transfection, we measured nitrite and lipoperoxide levels in the SN. We used ELISA to quantify the levels of
TNF-α, IL-1β, IL-6, endogenous rat CDNF (rCDNF) and hCDNF. We also used qRT-PCR to measure rCDNF and
hCDNF transcripts, and immunofluorescence assays to evaluate iNOS, CDNF and glial cells (microglia, astrocytes
and Neuron/Glial type 2 (NG2) cells). Intact SNs were additional controls.
Results: In the SN, 6-OHDA triggered nitrosative stress, increased inflammatory cytokines levels, and activated the
multipotent progenitor NG2 cells, which convert into astrocytes to produce rCDNF. In comparison with the
hemiparkinsonian rats that were transfected with the EGFP gene or without transfection, 6-OHDA treatment and
p3xNBRE-hCDNF transfection increased the conversion of NG2 cells into astrocytes resulting in 4-fold increase in the
rCDNF protein levels. The overexpressed CDNF reduced nitrosative stress, glial markers and IL-6 levels in the SN, but
not TNF-α and IL-1β levels.
Conclusion: Our results show the anti-inflammatory effect of CDNF in a 6-OHDA rat of Parkinson? s disease. Our results
also suggest the possible participation of TNF-α, IL-1β and IL-6 in rCDNF production by astrocytes, supporting their
anti-inflammatory role.
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Cerebral dopamine neurotrophic factor (CDNF) and mes-
encephalic astrocyte-derived neurotrophic factor (MANF)
are evolutionarily-conserved proteins that form the new
family of neurotrophic factors with unique structure [1-8].* Correspondence: martinez.fong@gmail.com
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unless otherwise stated.The main distinguishing feature of this family is that the
members (CDNF and MANF) contain eight cysteine resi-
dues that were conserved in evolution from invertebrates
to vertebrates [6,7]. CDNF was first identified by bioinfor-
matics tools and was then characterized biochemically
[2]. Pre-CDNF protein is 187 amino acids long whereas
mature CDNF protein (GenBank access: NM_177647)
comprises 161 amino acid residues with the molecular
weight of 18 kDa. The mature CDNF protein consists of
an N-terminal saposin-like domain that may bind lipids
and a C-terminal domain that is structurally similar to
members of the SAP protein superfamily [9]. Althoughtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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endoplasmic reticulum (ER) retention signal [6,8] and are,
therefore, located mainly in the ER. Neuroprotective and
neurorestorative effects of striatal CDNF injections were
demonstrated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyr-
idine (MPTP)-treated mice [10]. In 6-hydroxydopamine
(6-OHDA)-induced parkinsonian rat models, intrastriatal
CDNF gene therapy mediated by viral vectors [11,12] and
intrastriatal injection of CDNF protein as a single dose [2]
or chronic infusion [13] also showed protective effects.
CDNF gene therapy has shown a regenerative effect in the
rat sciatic nerve injury model [14]. In addition to the
neurotrophic effects, recent studies on primary glial cell
cultures suggest that CDNF has an anti-inflammatory ef-
fect [15,16]. However, it remains unknown whether CDNF
is able to revert from neuroinflammation in vivo and in an
animal model of Parkinson? s disease (PD).
Clinical, experimental, epidemiological, and pathological
evidence indicates that neuroinflammation plays an im-
portant role in PD [17-22]. Postmortem studies have
shown the presence of activated microglia and reactive
astrocytes [17-22]. Accordingly, increased levels of ni-
tric oxide (NO), inducible nitric oxide synthase (iNOS),
cyclooxygenase 2 (COX2) and pro-inflammatory cyto-
kines have been found in the brains of PD patients [23].
A similar inflammatory pattern has been found in the
rat SN after the striatal injection of 6-OHDA [24-29].
In this model, the role of the increased levels of pro-
inflammatory cytokines is controversial because recent
studies have shown that those cytokines in the neuro-
degenerative process can exert protective effects acting
as neurotrophic factors [30-32].
After injury, mature astrocytes can proliferate and
acquire stem cell properties suggesting their capacity to
promote neuronal regeneration [33-35]. Other cells that
have been involved in neuronal regeneration are pre-
cursor cells called Neuron/Glial type 2 (NG2) glia.
These NG2 glia are multipotent progenitor cells [36,37]
with neurogenic [38], oligodendrogenic [39,40], astro-
genic [41,42] and microgliogenic [43] properties. How-
ever, the role of NG2 cells has not been fully examined
in the 6-OHDA PD rat model. A recent study has only
shown that an intrastriatal 6-OHDA injection stimu-
lates the conversion of NG2 cells into microglia, which
produce GDNF, a neurotrophic factor for dopaminergic
neurons [43]. However, conversion ability of NG2 cells
to produce astrocytes that lead to the production of
neurotrophic factors in PD and animal models of this
disease remains unclear.
Neurotensin (NTS)-polyplex is a synthetic nanocarrier
that enables gene delivery via internalization of NTS
receptor type 1 into dopaminergic neurons in the sub-
stantia nigra (SN) and in primary cultures [44-48]. Some
studies have shown that NTS-polyplex is an efficienttool to transfer neurotrophic factor genes such as GDNF,
BDNF or Neurturin (NRTN) into dopaminergic neurons
after inducing lesion by an intrastriatal 6-OHDA injec-
tion [44,49]. In these models of neurotrophic factor gene
therapy, the transgene expression has been correlated
with a decrease of motor impairment, increase in DA
levels and recovery of nigrostriatal dopaminergic system
from a neurodegeneration [44,49]. The safety of NTS-
polyplex-mediated transfection is an added advantage
[50]. A recent work has shown that a 15-day period fol-
lowing the single intrastriatal injection of 6-OHDA is
very critical for the development of apoptosis and glia
activation in the SN [51]. Based on all the antecedents,
we hypothesized that the intranigral transfection of the
human CDNF (hCDNF) gene in the 6-OHDA PD animal
model would decrease neuroinflammation and shows
the participation of NG2 cells in overexpression of
CDNF. The hCDNF gene transfection was attained using
NTS-polyplex in the SN at day 15 after the intrastriatal
injection of 6-OHDA and, at day 15 post-transfection,
nitrosative/oxidative stress markers, pro-inflammatory
cytokines (TNF-α, IL-1β and IL-6), glial activation, en-
dogenous and transgenic CDNF levels were determined
in the SN of male Wistar rats. Our work uncovers the
in vivo anti-inflammatory role of CDNF during the crit-
ical period for dopaminergic neuronal survival in an ani-
mal model of PD.Methods
Plasmids
Plasmids p3xNBRE-hCDNF (4,482 bp) coding for hCDNF
and p3xNBRE-EGFP (4,684 bp) coding for EGFP (en-
hanced green florescent protein), a reporter gene, were
obtained by cloning the human CDNF cDNA (GenBank
access: NM 001029954) or the EGFP cDNA (GenBank
access: U55762) under the 3xNBRE (a synthetic and tissue
specific promoter based on Nurr1 element response) pro-
moter in the plasmid pGL2 basic 3xNBRE-LUC. LUC
cDNA was removed by Hind III - PflM I restriction en-
zymes (REs) from the pGL2 basic 3xNBRE-LUC, whereas
hCDNF cDNA (560 bp) was excised by Hind III - EcoR V
REs from pCR3.1-hCDNF and EGFP cDNA (716 bp) by
Hind III - Not I REs from pEGFP-N1 (Clontech; Mountain
View, CA, USA). The cohesive ends resulting from PflM I
and Not I digestion were treated with Klenow fragment
(Thermo Scientific; Mexico City, Mexico) to convert them
into blunt ends. hCDNF cDNA or EGFP cDNA were
cloned in the sense orientation into the Hind III - PflM I
sites in the plasmid pGL2 basic 3xNBRE-LUC, replacing
LUC gene. Restriction digestion and automatic DNA se-
quencing confirmed full hCDNF and EGFP sequences and
their correct orientation in the plasmids. Transfections
with pCR3.1-hCDNF, encoding hCDNF gene under CMV
Figure 1 Experimental design. At day 0, we injected 6-hydroxydopamine
(6-OHDA) into the striatum; at day 15 post-lesion, we transfected
either of the mentioned plasmids with neurotensin (NTS)-polyplex
into the substantia nigra pars compacta and at day 30 from the
beginning of the experiment or at day 15 after the transfection,
we extracted the tissues or perfused the animals for molecular and
cellular assays.
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a positive and negative controls respectively.
Synthesis of the neurotensin carrier and polyplexes
The detailed procedure of NTS carrier synthesis and of
NTS-polyplex formation at an optimum molar ratio
and its biophysical characteristics were reported previ-
ously [45,47,48]. Briefly, NTS (Sigma-Aldrich; St Louis,
MO, USA) and FP (GLFEAIAEFIEGGWEGLIEGCAKKK;
purity > 90%; SynPep Corp.; Dublin, CA, USA) were
cross-linked with poly-L-lysine (48 kDa mean molecular
mass; Sigma-Aldrich; St Louis, MO, USA) using LC-SPDP
(Thermo Scientific Pierce; Rockford, IL, USA) as the
cross-linker [45]. Suitable gel-filtration chromatography
was used to purify the SPDP-derivatives and the NTS-
SPDP-(FP-SPDP)-poly-L-lysine conjugate, the NTS car-
rier. This conjugate was concentrated to 1 mL, further
dialyzed against PBS solution, pH 7.4, and sterilized by
filtration. The NTS-polyplexes were made by electrostati-
cally binding the mutant Vp1 SV40 KP (MAPTKRKGSCP-
GAAPNKPK; 90% purity; SynPep Corp., Dublin, CA, USA)
to pDNA [45,47,52]. Retardation and retention gel assays
were used to determine and calculate the optimal molar
ratio of polyplex components as described in detail else-
where [45,47,48,52,53]. Accordingly, the final optimum
molar ratio of NTS-polyplex components for all the plas-
mids used were 30 nM pDNA: 36 μM KP: 900 nM NTS-
carrier and, at this molar ratio, the concentration of
NTS used was 385.6 pmol/μL, calculated as per 125I-NTS
[47,50]. Based on the concentration and size of pDNAs,
the dose of pDNA injected was 88 ng/μL of p3xNBRE-
hCDNF (4,482 bp), 111 ng/μL of pCR3.1-hCDNF
(5,624 bp) and 92.7 ng/μL of p3xNBRE-EGFP (4,684 bp).
Intracranial injections
Male Wistar rats (200 to 230 g) housed together (5 per
cage) with constant temperature (23?C), water and food
available ad libitum and kept under natural light-dark cycle
(12-12 hours) were used. Rats were anesthetized with keta-
mine/xilazine (100 mg/kg/60 mg/kg intraperitoneally) and
placed on a stereotaxic frame (Stoelting; Wood Dale, IL,
USA). The hemiparkinsonism was generated by injecting
single dose of 6-OHDA solution (Sigma-Aldrich; St Louis,
MO, USA) (20 μg/3 μL of PBS containing 0.2% ascorbic
acid) into the left striatum at the following coordinates:
AP +6.9 mm from interaural midpoint, ML +4.0 mm from
intraparietal suture, DV −5.5 mm from dura mater. The
flow rate of injection was 0.2 μL/minute [51].
NTS-polyplex harboring the plasmid p3xNBRE-hCDNF
was injected at day 15 after the lesion with 6-OHDA
(referred as L15T15; Figure 1) because the maximum peak
of apoptosis and activated glial cells was detected at that
day [51]. The injection was made into the ipsilateral SN at
the following coordinates: AP, +2.4 mm from interauralmidpoint; ML, +1.8 mm from intraparietal suture,
DV −6.9 mm from dura mater. Three microliters of
NTS-polyplex solution were injected at a flow rate of
0.1 μL/minute. NTS-polyplex harboring the plasmids
p3xNBRE-EGFP, labeled as L15FT15 (Figure 1), and
pCR3.1-hCDNF, labeled as L15OT15 (Figure 1), were
also injected to maintain negative and positive controls
respectively. Detailed experimental scheme was shown in
Figure 1.
qRT-PCR (quantitative Reverse TranscriptionPolymerase
Chain Reaction)
Total RNA was isolated from the brain tissues (striatum
and SN) using Trizol (Invitrogen Corporation, Carlsbad,
CA, USA) and then RNA preparations were treated with
RNase-free DNase I. Reverse transcription was made
with 750 ng of total RNA for striatum and 250 ng of
total RNA for SN with SuperScript III reverse transcript-
ase (200 U) using 0.1 mg of oligo dT (Invitrogen Cor-
poration, Carlsbad, CA, USA). The reverse transcribed
product was diluted 4 times with molecular biology
grade water and 2.5 μL of this diluted cDNA was mixed
with 2? TaqMan Universal Mastermix and 20? TaqMan
gene specific probe (Applied Biosystems; Foster City,
CA, USA) in a final volume of 5 μL. cDNAs were ampli-
fied for 45 cycles using a 7900HT Fast Real Time PCR
system (Applied Biosystems; Foster City, CA, USA).
TaqMan gene specific probes used for experiments were:
Rn00667869_m1 for rat β-actin; Rn01525859_g1 for rat
TNF-α; Rn00580432_m1 for rat IL-1β; Rn01410330_
m1 for rat IL-6; Rn01765001_m1 for rat CDNF and
Hs00418490_m1 for human CDNF (Applied Biosystems;
Foster City, CA, USA). β-Actin mRNA levels were also
amplified for each sample and used as internal control
and for normalization. The cycle threshold (Ct) values
for β-actin, rCDNF and hCDNF were measured and
calculated by Sequence Detection System software (SDS
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transcript levels were expressed as the fold-change for
gene expression and were calculated using the 2-ΔΔCt
method [54,55]. For the untreated control samples, ΔΔCt
equals 0 and 20 is 1, the fold change in rCDNFgene ex-
pression in intact condition is 1 [56].
ELISA
Homogenization of brain tissues (striatum and SN) was
made using protein extraction buffer containing 100 mM
Tris HCl (pH 7.4), 750 mM NaCl (sodium chloride),
10 mM EDTA (ethylenediaminetetraacetic acid), 5 mM
EGTA (ethylene glycoltetraacetic acid) and a cocktail of
protease inhibitors (Roche, Basel, Switzerland) [57]. The
samples were centrifuged at 1,000 g for 10 minutes at 4?C
and then supernatant was centrifuged again at 20,000 g
for 40 minutes at 4?C to remove the remaining debris. For
detecting the levels of inflammatory cytokines, indirect
ELISA was done as per the user guide using Milliplex
MAP Rat cytokine/chemokine magnetic bead panel kit
(RECYTMAG_65K; Millipore; Temecula, CA, USA) and
reading was done by LUMINEX MAGPIX? detection
system with xPONET software (Millipore Corporation;
Billerica, MA, USA). Sensitivity of TNF-α ranges between
1.9 to 156.3 pg/mL, of IL-1β ranges between 2.8 to
2,500.0 pg/mL and of IL-6 ranges between 30.7 to
4,687.5 pg/mL. For detecting the levels of hCDNF and
rCDNF, Sandwich enzyme immunoassay was done using
separate kits (SEG458Hu and SEG458Ra; Uscn Life
Science Inc; Wuhan, Hubei, China) and absorbance was
read at 450 nm using a Multiskan? MULTISOFT spectro-
photometer (Labsystems; Tokyo, Japan).
Immunofluorescence
Serial coronal sections of 30-μm thickness were cut from
perfused and fixed rat brains with 4% paraformaldehyde.
Before starting the experiment, the slices were rinsed once
with PBS 1? for 5 minutes. To increase the permeability of
reagents into the tissue, the slices were incubated with
PBS-Triton 0.1% for 20 minutes and then by PBS-SDS
0.5% for 5 minutes. These permeabilized sections were
incubated with 1% BSA in PBS-Triton 0.1% for 30 minutes
to block the unspecific binding sites. Immediately after
blocking, primary antibody solution was added to the tissue
slices and was incubated overnight at room temperature on
a rotary shaker. This is followed by addition of secondary
antibody and incubated for 2 hours at room temperature
on a rotary shaker. Between each step, washing with PBS
(1x)was done ? 3 for 5 minutes each.
For all double and triple immunofluorescence experi-
ments, primary antibodies used were mouse monoclonal
anti-tyrosine hydroxylase (TH), clone TH-2, ascites fluid
(1:1,000; Sigma-Aldrich; St Louis, MO, USA), rabbit poly-
clonal anti-TH (1:1,000; Chemicon Inc.; Billerica, MA,USA), rabbit polyclonal anti-CDNF (1:1,000; ProSci Inc;
San Diego, CA, USA), mouse monoclonal anti-iNOS
(1:1,000; BD Transduction Laboratories; BD Biosciences;
San Jose, CA, USA), mouse monoclonal anti-CD11b
(OX42), a marker for microglia (1:200; Abcam; Cam-
bridge, UK), rabbit polyclonal anti-OX42 (1:250; Abcam;
Cambridge, UK), goat polyclonal anti-OX42 (1:300;
Abcam; Cambridge, UK), mouse monoclonal anti-glial fi-
brillary acidic protein (GFAP) (1:250; Cell Signaling; Dan-
vers, MA, USA), rabbit polyclonal anti-GFAP (1:300; Cell
Signaling; Danvers, MA, USA), goat polyclonal anti-GFAP
(1:300; Cell Signaling; Danvers, MA, USA), mouse mono-
clonal anti-NG2 (1:1,000; Upstate Cell Signaling solutions;
Temecula, CA, USA) and rabbit polyclonal anti-NG2
(1:300; Millipore; Temecula, CA, USA). Irrelevant anti-
body of the same IgG subclass was added in place of pri-
mary antibody for all the negative controls.
The secondary antibodies used were Texas red anti-
mouse IgG (H + L) made in horse (1:900; Vector Labora-
tories; Burlingame, CA, USA), Texas red anti-rabbit IgG
(H + L) made in goat (1:400; Vector Laboratories; Burlin-
game, CA, USA), Texas red anti-goat IgG (H + L) made
in donkey (1:500; Vector Laboratories; Burlingame, CA,
USA), Alexa Fluor 488 anti-mouse IgG (H + L) made in
chicken (1:200; Invitrogen Molecular Probes; Eugene,
OR, USA), Alexa Fluor 488 anti-rabbit IgG (H + L) made
in chicken (1:200; Invitrogen Molecular Probes; Eugene,
OR, USA), Alexa Fluor 488 anti-goat IgG (H + L) made
in donkey (1:500; Invitrogen Molecular Probes; Eugene,
OR, USA), Cy3 anti-mouse IgG (H + L) made in goat
(1:300; Invitrogen Molecular Probes; Eugene, OR, USA).
Fluorescence labeling was viewed through a multispec-
tral confocal laser-scanning microscope (TCS-SPE, Leica;
Heidelberg, Germany) using 40? and 63? oil-immersion
objectives at excitation-emission wavelengths of 405 to
465 nm (blue channel), 488 to 522 nm (green channel),
and 568 to 635 nm (red channel). Their consecutive 1-μm
optical sections were also obtained in the z-series (scan-
ning rate 600 Hz). The images were acquired using LAS
AF software (Leica application suite; Leica Microsystems,
Nussloch, Germany). Quantification was made using the
same LAS AF software by placing a rectangular region of
interest (ROI) across the full image and within the ROI,
for every image, mean fluorescence intensity (MFI) was
measured and the values plotted.
Nitrite assay
The content of nitric oxide (NO) was determined by meas-
uring the accumulation of nitrites (NO2
−) in the supernatant
of homogenized SN samples of rat brain using the colori-
metric method as described elsewhere [58]. Briefly, tissue
samples from SN were mechanically homogenized in PBS
and centrifuged at 12,500 rpm for 30 minutes at 4?C by
using 17TR microfuge (Hanil Science Industrial Co. Ltd;
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natant was measured by the colorimetric reaction gener-
ated by the addition of 100 μL of Griess reagent (composes
equal volumes of 0.1% N-(1-naphthyl) ethylenediamine
dihydrochloride and 1.32% sulfanilamide in 60% acetic
acid). The absorbance of the samples was determined
at 540 nm with a SmartSpec 3000 spectrophotometer
(Bio-Rad; Hercules, CA, USA) and interpolated by using a
standard curve of sodium nitrite (NaNO2; 1 to 10 μM) to
calculate the nitrite content.Lipoperoxide assay
Assay of lipoperoxide was made by measuring malon-
dialdehyde (MDA) and 4-hydroxyalkanal (4-HEA) in the
supernatant of homogenized SN samples of rat brain
using the colorimetric method [58]. Briefly, the colori-
metric reaction in 200 μL of supernatant was produced
by subsequent addition of 0.65 mL of 10.3 mM N-me-
thyl 2-phenylindole diluted in a mixture of acetonitrile:
methanol (3:1). The reaction was initiated by the
addition of 150 μL of methanesulfonic acid. This reac-
tion mixture was strongly agitated and incubated at 45?C
for 1 hour and then centrifuged at 3,000 rpm for 10 mi-
nutes. The absorbance of supernatant was read at
586 nm with a SmartSpec 3000 spectrophotometer (Bio-
Rad; Hercules, CA, USA). The absorbance values were
compared to a standard curve in the concentration
range of 0.5 to 5 μM of 1,1,3,3-tetramethoxypropane
(10 mM stock) to calculate the MDA and 4-HEA con-
tents in the samples.Figure 2 Presence of total cerebral dopamine neurotrophic factor (CD
confocal micrographs showing the immunoreactivity to tyrosine hydroxyla
(green). TH/CDNF is the overlay of the micrographs in the same row. Untra
different intact rat brains. The scale bars = 20 μm are common for all the mEthics statement
All procedures were in accordance with the current
Mexican legislation, NOM-062-ZOO-1999 (SAGARPA),
based on the Guide for the Care and Use of Laboratory
animals, NRC. CINVESTAV Institutional Animal Care
and Use Committee approved our procedures for animal
use (protocol # 109-02). All efforts were made to minimize
animal suffering.
Statistical analysis
All results were expressed as mean ? standard deviation
(SD) values, obtained at least from 4 independent exper-
iments (n = 4). The comparison among the groups was
made using one-way analysis of variance (ANOVA)
followed by the Newman-Keuls post hoc test using the
GraphPad Prism 5.0 (GraphPad Software Inc., La Jolla,
CA, USA). Accepted significance was at P < 0.05.
Results
Pattern and levels of total CDNF expression in the SN
The immunofluorescence studies in the untransfected
SN of intact rats showed that CDNF+ cells do not co-
localize with cells immunoreactive to TH, the rate-
limiting enzyme in dopamine synthesis (Figure 2, top
row), but largely co-localize with TH+ cells 7 days after
p3xNBRE-hCDNF transfection (Figure 2, bottom row).
These results show the feasibility of targeted hCDNF
gene delivery (Figure 2). As the endogenous presence of
rat CDNF (rCDNF) was found in an intact rat brain, it
was very important to explore whether the 6-OHDA lesion
and the hCDNF transfection influence the endogenousNF) + cells in intact rat substantia nigra (SN). Representative
se (TH), the rate-limiting enzyme in dopamine synthesis (red) and CDNF
nsfected and p3xNBRE-hCDNF transfected tissue slices were from
icrographs.
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detect both rCDNF and hCDNF, we used species-specific
probes and kits for qRT-PCR and ELISA assays respectively
for the experimental groups.
qRT-PCR assays in the SN at day 30 after lesion (L30)
showed 2-fold increase (2.162 ? 0.103) in rCDNF tran-
scripts than basal levels in intact condition. At this time,
an additional increase (3.559 ? 0.037) in 6-OHDA-induced
levels of rCDNF transcripts in the SN was found at day 15
after transfection with p3xNBRE-hCDNF (L15T15), but
not (1.107 ? 0.066) with a reporter gene (L15FT15 ) trans-
fection (Figure 3A). Surprisingly, the qRT-PCR assays
showed that hCDNF mRNA expression was transient,
when transfected at day 15 after 6-OHDA lesion
(Figure 3B). High levels of hCDNF transcripts were mea-
sured at 6 hours (0.149 ? 0.008) after transfection, and
these levels reduced almost to half after 24 hours (0.058 ?
0.008) and were maintained until 3 days (0.058 ? 0.004)
after transfection to disappear thereafter (Figure 3, B). At
the same time, the highest hCDNF protein levels were
measured at 6 hours (0.56 ? 0.04 ng/mL) and at 24 hours
(0.599 ? 0.024 ng/mL) after transfection, but the levels
started to decrease at day 3 (0.538 ? 0.021 ng/mL) and
further decreased until L15T15 (0.150 ? 0.001 ng/mL)
(Figure 3D). However, no significant change in rCDNF
protein levels was found among intact (10.97 ? 0.19
ng/mL), L30 (11.63 ? 0.19 ng/mL) and L15FT15 (11.95 ?
0.29 ng/mL) conditions. A 6-fold increase in rCDNF pro-
tein levels was detected in L15T15 (66.08 ? 2.29 ng/mL),
when compared to those in intact condition (Figure 3C).
Together, these results suggest that the transient transgene
expression triggered the expression of endogenous rCDNF.
Double immunofluorescence studies showed that CDNF
immunoreactivity exhibits different cellular location in the
SN under different experimental conditions. In the SN
pars compacta (SNc) of an intact rat, CDNF+ cells were
absent and instead they are present in the parabranchial
pigmented (PBP) nucleus, a nucleus in medial ventral
tegmental area that borders SNc ventrally (Figure 3E, top
row). In L30 (Figure 3E top row) and L15T15 (Figure 3E,
top row) conditions, CDNF immunoreactivity is present in
and around TH+ cells in the SNc. In the SNc/SN reticulata
(SNr) inter-region, CDNF immunoreactivity is absent in in-
tact rats but present in L30 and L15T15 (Figure 3E, bottom
row). Especially in this inter-region of SNc/SNr, the morph-
ology of CDNF+ cells was suggestive of glial cells and their
branches are more notable in L15T15 but less evident in
L30 (Figure 3E, bottom row).
Activation and conversion of NG2 cells into astrocytes
that produce CDNF in the SNr
6-OHDA toxicity is known to activate various glial cell
types [51]. Accordingly, confocal analysis showed the
presence of NG2+ cells (Figure 4, NG2) and GFAP+ cells(Figure 3, GFAP) in the SNr 30 days after lesion (L30),
and co-localization of these cells as shown by the merged
images (Figure 4, middle row) and by z optical sections
(Figure 4, bottom row). In intact SNr, NG2+ cells and
NG2/GFAP double positive cells were absent and only a
basal number of GFAP+ cells were found (Figure 5A).
These results suggest that the 6-OHDA lesion induced the
conversion of NG2 cells into astrocyte cells (Additional
file 1: Figure S1).
We further explored whether NG2/GFAP double posi-
tive cells might produce CDNF. Remarkably, rCDNF is
produced by astrocytes in intact rat SNr (Figure 5A). In
L30, rCDNF+ cells were also NG2/GFAP double positive
cells (Figure 5B). Interestingly, in L15T15, there was pro-
found branching of NG2/GFAP/CDNF triple positive cells
(Figure 5C), thus suggesting that transfection of hCDNF
leads to conversion of more NG2 cells to astrocytes, which
lead to increased production of rCDNF (Figure 3A and
Figure 3C). Mean fluorescence intensity (MFI) for NG2
(Figure 5D) showed 5-fold increase with 6-OHDA lesion
in L30 (18.05 ? 2.12) when compared to that of intact
condition (3.73 ? 0.31), and further 2-fold increase with
hCDNF transfection (45.85 ? 2.74) when compared to that
of L30. MFI for GFAP (Figure 5E) increased double
(38.3 ? 2.3) with lesion and almost triple (48.97 ? 1.36)
with transfection when compared to that of basal levels in
the intact condition (18.42 ? 1.52). Whereas, MFI for
CDNF (Figure 5F) showed no significance in L30 (39.04 ?
1.57) but increased almost double in L15T15 (57.1 ? 2.6),
when compared to intact condition (38.37 ? 2.05), support-
ing the ELISA results (Figure 3C). On the other hand,
neither this phenomenon of conversion of NG2 cells to
microglia to produce CDNF, nor NG2/OX42/CDNF triple
positive cells were found at L15T15 (Additional file 2:
Figure S2).
In addition, we explored at day 15 after transfection
whether this production of CDNF by astrocytes and
astrocyte-like NG2 cells depends on transgene or pro-
moter. Transfection of hCDNF under CMV, a non-specific
promoter, did not show the presence of NG2+ cells, but
showed a slight increase in CDNF immunoreactivity in
GFAP+ cells (Additional file 3: Figure S3, A) when com-
pared to that in intact tissue (Figure 5A). However, this
was less than that produced by the hCDNF transfection
under control of 3xNBRE promoter (Figure 5C and
Additional file 3: Figure S3C), while the transfection of
EGFP under 3xNBRE promoter showed similar effects
(Additional file 3: Figure S3B) as observed in L30
(Figure 5B). MFI for NG2 (Additional file 3: Figure S3D)
showed around 10-fold and 15-fold increase with
p3xNBRE-EGFP (30.72 ? 1.82) and with p3xNBRE-hCDNF
(45.85 ? 2.74) respectively, when compared to that of
pCR3.1-hCDNF (2.65 ? 0.74) transfection. MFI for CDNF
(Additional file 3: Figure S3F) showed approximately 2-fold
Figure 3 (See legend on next page.)
Nadella et al. Journal of Neuroinflammation 2014, 11:209 Page 7 of 18
http://www.jneuroinflammation.com/content/11/1/209
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Figure 3 Expression levels of total cerebral dopamine neurotrophic factor (CDNF) in the substantia nigra (SN). Graphs showing the fold
change increase in the endogenous, rat (r)CDNF (A) and relative transgene human (h)CDNF (B) transcripts by qRT-PCR. Graphs showing the
protein levels of rCDNF (C) and hCDNF (D) by ELISA. First 3 bars in the graphs represent controls and the rest represent the time course of
p3xNBRE-hCDNF transfections. FT15 = at day 15 after p3xNBRE-EGFP transfection, ? = at 6 hours; 1 = at 24 hours; 3 = at day 3; 7 = at day 7; 15 = day 15,
after p3xNBRE-hCDNF transfection in a 15-day lesion rats. (E) Representative merged confocal micrographs showing immunoreactivity to CDNF (green)
and tyrosine hydroxylase (TH) (red). The headings refer to mesencephalon slices that were obtained from different rats, intact (INTACT), with 30-day
6-OHDA lesion (L30), and 15 days of lesion and 15 days of transfection (L15T15). The scale bars = 20 μm are common for all the micrographs. ns = not
significant. **P < 0.01, ***P < 0.001 when compared with the intact condition. ? = P < 0.001 when compared with L30. One-way ANOVA with
Newman-Keuls post hoc test. n = 4 different rats for each condition.
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and with p3xNBRE-hCDNF (57.1 ? 2.6) respectively, when
compared to that of pCR3.1-hCDNF (22.15 ? 5.62) trans-
fection. Whereas, MFI for GFAP (Additional file 3: Figure
S3E) showed no significance at L15FT15 (35.8 ? 1.97) but a
significant increase at L15T15 (48.97 ? 1.36), when com-
pared to that at L15OT15 (35.99 ? 3.05). These results sug-
gest that the combination of hCDNF gene and 3xNBRE
promoter is responsible for the increased production of
endogenous rCDNF by astrocyte-like NG2 cells as this
phenomenon is less pronounced with a reporter gene and
absent with CMV promoter.Figure 4 Apparent conversion of NG2 cell into an astrocyte cell
in the substantia nigra pars reticulata (SNr) at day 30 after
6-hydroxydopamine (6-ODHA) lesion. Representative confocal
micrographs showing nuclei stained with Hoechst (blue) and
immunostaining against NG2 (green), and GFAP (red). Individual
micrographs of NG2 and GFAP (top row), merged images of
Hoechst/NG2/GFAP and NG2/GFAP (middle row) and vertical 1-μm
optical slices for the cell indicated by the asterisk (bottom row) are
shown. The scale bar = 20 μm is common for all the micrographs.
GFAP, glial fibrillary acidic protein; NG2, Neuron/Glial type 2.hCDNF transfection reduces nitrosative stress in the SN
We evaluated iNOS immunoreactivity and nitrite levels
as markers for nitrosative stress and MDA levels as a
marker for oxidative stress (lipoperoxidation). Merged
confocal micrographs of double immunofluorescence in
intact SNc showed the presence of iNOS immunoreactiv-
ity in OX42+ cells and its absence in other glia cells and
in TH+ neurons (Figure 6A). In L30, increased iNOS im-
munoreactivity was found in OX42+ cells (Figure 6B)
when compared to that in intact condition (Figure 6A).
p3xNBRE-hCDNF transfection reduced both the presence
of iNOS and activated glial population-like NG2 cells, as-
trocytes and microglia in the SNc (Figure 6C). Supporting
this, MFI for iNOS (Figure 6D) showed a 3-fold increase
with 6-OHDA lesion (9.385 ? 0.191) and reduced almost
near to the basal values with hCDNF transfection
(3.53 ? 0.44) when compared to intact condition (2.975 ?
0.222). The hCDNF transfection (0.309 ? 0.086 nmol/mg)
also significantly decreased the nitrite levels induced
(0.83 ? 0.05 nmol/mg) by the lesion (L30) to the basal
>values (0.343 ? 0.144 nmol/mg) measured in the intact
SN (Figure 6E). No significant difference was found in
the levels of lipoperoxide markers at the time points
of the study (Figure 6F). These results suggest that tran-
sient CDNF expression reduces nitrosative stress in the
midbrain.hCDNF transfection reduces activated glial cells in the SNc
As TH+ cells are in the SNc, we used TH immunostain-
ing to locate that region. In intact rat SNc, all the glial
cell markers like NG2 (4.135 ? 0.345), OX42 (13.8 ? 0.3)
and GFAP (10.44 ? 0.53) were present in low/basal levels
as per MFI (Figure 6A; Figure 7C,D,E). In L30 SNc, the
double immunofluorescence studies showed the pres-
ence (Figure 7A) and 6-fold increase (28.86 ? 1.39) in
NG2+ cells (Figure 7C), around 2-fold increase (23.23 ?
2.53) in OX42+ cells (Figure 7D) and 8-fold increase
(75.79 ? 1.85) in GFAP+ cells (Figure 7E), indicating the
activation of glial cells due to 6-OHDA injection. The
transfection of p3xNBRE-hCDNF significantly reduced
the presence of NG2+ cells (5.438 ? 0.401) and OX42+
cells (14 ? 2) (Figure 7B) and their respective MFI to the
basal levels (Figure 7C and D). The transfection also
Figure 5 (See legend on next page.)
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and MFI of GFAP+ cells (31.89 ? 2.05) almost to half
(Figure 7E). These results suggest the inactivation of glialcells because of p3xNBRE-hCDNF transfection. No co-
localization of markers was observed in either of the ex-
perimental conditions. The effect of p3xNBRE-hCDNF
(See figure on previous page.)
Figure 5 Expression of cerebral dopamine neurotrophic factor (CDNF) by astrocytes and astrocyte-like NG2 cells in the substantia nigra
pars reticulata (SNr). Representative merged confocal micrographs showing immunoreactivity to CDNF (green), GFAP (red) and NG2 (blue). The
triple immune micrographs in the lower row are shown individually in the first three rows with possible combinations of double markers to see
more details. The headings refer to mesencephalon slices that were obtained from different rats, intact (A), with 30-day 6-OHDA lesion (B), and
15 days of lesion and 15 days of transfection (C). Asterisk represents the cell whose fluorescent markers are individually displayed in the inserts.
Graphs showing the mean fluorescence intensity (MFI) for NG2 (D), GFAP (E) and CDNF (F). The scale bars = 20 μm are common for all the
micrographs. ns = not significant. ***P < 0.001 when compared with the intact condition. ? = P < 0.001 when compared with L30. One-way
ANOVA with Newman-Keuls post hoc test. n = 4 different rats for each condition. GFAP, glial fibrillary acidic protein; NG2, Neuron/Glial type 2.
Figure 6 Nitrosative and oxidative stress markers in the substantia nigra (SN). Representative merged confocal micrographs showing the
presence of inducible nitric oxide synthase (iNOS) + cells (green) with tyrosine hydroxylase (TH) + cells (red) in first row, with NG2+ cells (red) in
the second row, with GFAP+ cells (red) in the third row, and with OX42+ cells (red) in the last row in intact (A), in L30 (B) and in L15T15
(C) conditions. Graphs showing the mean fluorescence intensity (MFI) for iNOS (D), the levels of nitrites (E) and malondialdehyde (F). The
headings for micrograph panels and x-axis labels for graphs refer to mesencephalon slices that were obtained from different rats, intact, with 30-day
6-hydroxydopamine (6-OHDA) lesion, L30, and 15 days of lesion and 15 days of transfection, L15T15. The scale bars = 20 μm are common for all the
micrographs. ns = not significant. *P < 0.05, **P < 0.01, ***P < 0.001 when compared with the intact condition. ? = P < 0.01, ? = P < 0.001 when
compared with L30. One-way ANOVA with Newman-Keuls post hoc test. n = 4 different rats for each condition. GFAP, glial fibrillary acidic protein; NG2,
Neuron/Glial type 2.
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Figure 7 Presence of glial cells in the substantia nigra pars compacta (SNc). Representative merged confocal micrographs showing the
presence of NG2+ cells (green) with TH+ cells (red, top row), with OX42+ cells (red, middle row), and with GFAP+ cells (red, bottom row) at day
30 after lesion, L30 (A) and at day 15 after transfection with 15 days of lesion, L15T15 (B). Graphs showing the mean fluorescence intensity (MFI)
for NG2 (C), OX42 (D) and GFAP (E). The scale bars = 20 μm are common for all the micrographs. ns = not significant. ***P < 0.001 when
compared with the intact condition. ? = P < 0.001 when compared with L30. One-way ANOVA with Newman-Keuls post hoc test. n = 4 different
rats for each condition. GFAP, glial fibrillary acidic protein; NG2, Neuron/Glial type 2.
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the SNr (Figure 5).
Expression levels of total CDNF in the striatum
In the intact striatum, GFAP+ and CDNF+ cells were
found, but GFAP/CDNF double positive cells and NG2+
cells were absent (Figure 8A). In addition, the morph-
ology of CDNF+ cells was different from that of GFAP+
and NG2+ cells (Figure 8A), suggesting that astrocytesdo not produce CDNF in the striatum. In contrast, in
L30, extended branching of NG2+ and GFAP+ cells col-
locating with CDNF+ cells: that is NG2/GFAP/CDNF
triple positive cells, were detected (Figure 8B). These
suggest that, similar to L30 SNr (Figure 5B), the
6-OHDA injection leads to the activation of glial cells in
the striatum. Interestingly, in L15T15, the immunofluores-
cence analysis showed the absence of NG2/GFAP/CDNF
triple positive cells yet there seemed to be an increase in
Figure 8 Expression levels of total cerebral dopamine neurotrophic factor (CDNF) in the striatum. Representative merged confocal
micrographs showing immunoreactivity to CDNF (green), GFAP (red) and NG2 (blue). The triple immune micrographs in the lower row are shown
individually in the first three rows with possible combinations of double markers to see more details in intact (A), in L30 (B) and in L15T15 (C)
conditions. Graphs showing rCDNF transcripts by qRT-PCR (D) and protein levels of rCDNF (E) and hCDNF (F) by ELISA. The headings for micrograph
panels and x-axis labels for graphs refer to mesencephalon slices that were obtained from different rats, intact, with 30-day 6-hydroxydopamine
(6-OHDA) lesion, L30, and 15 days of lesion and 15 days of transfection, L15T15. The scale bars = 20 μm are common for all the micrographs. ns = not
significant. ***P < 0.001 when compared with the intact condition. ? = P < 0.001 when compared with L30. One-way ANOVA with Newman-Keuls post
hoc test. n = 4 different rats for each condition. GFAP, glial fibrillary acidic protein; NG2, Neuron/Glial type 2.
Nadella et al. Journal of Neuroinflammation 2014, 11:209 Page 12 of 18
http://www.jneuroinflammation.com/content/11/1/209the number CDNF+ cells as compared with the intact and
L30 conditions (Figure 8C). Moreover, the morphology of
GFAP+ cells after transfection (Figure 8C) appears to be
similar as in an intact striatum (Figure 8A), indicating
inactivation of those glial cells by overexpressed CDNF.
Accordingly, qRT-PCR (Figure 8D) and ELISA (Figure 8E)
results showed an increase in the level of rCDNF tran-
scripts (15.16 ? 0.11) and proteins (55.94 ? 0.37 ng/mL) in
L15T15 when compared with those in intact (11.37 ?
0.95 ng/mL) and in L30 conditions (2.01 ? 0.02 and
11.41 ? 0.44 ng/mL). hCDNF protein (0.395 ? 0.093 ng/mL)was also detected in the striatum at L15T15 (Figure 8F),
suggesting the possible anterograde transport of hCDNF
protein from SN to the striatum.
Levels of Inflammatory cytokines in the nigrostriatal
system
Basal protein levels of TNF-α (0.991 ? 0.022 pg/mL in SN
and 1.751 ? 0.044 pg/mL in striatum), IL-1 β (147.8 ?
11.3 pg/mL in SN and 420.2 ? 80.5 pg/mL in striatum)
and IL-6 (350.3 ? 20.7 pg/mL in SN and 1,717 ? 155
pg/mL in striatum) were measured by indirect ELISA in
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? 0.16 pg/mL in SN and 2.248 ? 0.242 pg/mL in striatum),
IL-1β (272.6 ? 16.3 pg/mL in SN and 566 ? 17 pg/mL in
striatum) and IL-6 (933.9 ? 17.8 pg/mL in SN) protein
levels increased significantly (except for IL-6 in striatum)
when compared to that of intact condition (Figure 9A
and B), suggesting that this increase is due to the
6-OHDA lesion. Whereas in L15T15, hCDNF transfec-
tion could neither decrease those levels as expected nor
could reach basal levels as in intact condition. In L15T15
SN, IL-6 levels (783.3 ? 56.2 pg/mL) decreased, TNF- αFigure 9 Protein levels of inflammatory cytokines in the nigrostriatal
using indirect ELISA in the substantia nigra (SN) (A) and in the striatum (B
compared with the intact condition. ∂ = P < 0.05, ? = P < 0.01, ? = P < 0.00
post hoc test. n = 4 different rats for each condition.levels (1.64 ? 0.05 pg/mL) remained the same but IL-1 β
levels (339.3 ? 34.6 pg/mL) increased, when compared
with those in L30 (Figure 9, A). In L15T15 striatum, both
the levels of IL-6 (2,303 ? 83 pg/mL) and TNF- α (2.729 ?
0.246 pg/mL) increased but no significant change was
detected in IL-1β (642.2 ? 58.1 pg/mL) levels, when com-
pared with those in L30 (Figure 9B).
Discussion
The hypothetical view of CDNF as an ER stress response
protein [6] opened new research avenues in the field ofsystem. Graphs showing the protein levels of TNF-α, IL-1β, and IL-6
). ns = not significant, *P < 0.05, **P < 0.01, ***P < 0.001 when
1 when compared with L30. One-way ANOVA with Newman-Keuls
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CDNF was recently shown in cultures of lipopolysaccha-
ride (LPS)-stimulated microglia [16] and tunicamycin-
stimulated astrocytes [15]. To the best of our knowledge,
the anti-inflammatory role of CDNF has not yet been
shown either in vivo or in the 6-OHDA model. Therefore,
we have focused on anti-neuroinflammatory role of CDNF
in the rat 6-OHDA model and found that a single intrani-
gral transient transfection of hCDNF gene at critical
period, which is at day 15 after lesion [51], can reduce
neuroinflammatory markers. This reduction might be
accounted by the overexpression of endogenous rCDNF
due to the conversion of NG2 cells to astrocytes and
expression of hCDNF. The conversion of NG2 cells to as-
trocytes was reported in the spinal cord [39,59], in the
cerebellum [41] and in the cerebral cortex following a
penetrating brain injury [60], but not in other regions of
the brain. Supporting this feature, our work showed an
apparent conversion of NG2 cells to astrocytes in the SNr
of rats induced by the intrastriatal 6-OHDA lesion.
Neuroinflammatory processes and other pathophysio-
logical mechanisms of PD can be reproduced by 6-OHDA
in the rat [22,25,26]. Accordingly, a single intrastriatal in-
jection of 6-OHDA in our work also led to the activation
of various glial cells, the presence of nitrosative stress
markers and increase in the levels of inflammatory cyto-
kines. Interestingly, at day 30 after lesion, we found an
increase in the levels of rCDNF transcripts but no signifi-
cant change at protein level when compared to those in
intact SN and striatum. Among several reasons [61-63],
changes in the post-transcriptional control [64] or delayed
correlation [65] might explain the lack of correlation be-
tween mRNA and protein for rCDNF in L30 as those
samples were subjected to oxidative stress by 6-OHDA.
Supporting this, in L30, triple immunofluorescence results
showed conversion of NG2 cells into astrocytes to pro-
duce rCDNF in the SNr and in the striatum and these
levels seem to be the same as in the intact condition, as
were confirmed by ELISA and MFI quantification. These
results suggest that the endogenous production of rCDNF
in hemiparkinsonian rats was only to maintain the basal
levels, which were insufficient to halt the progression of
the neuroinflammatory response, as stress markers still
appear at this time point.
In our study, intranigral transfection of hCDNF gene
under the control of synthetic NBRE (that is Nurr1
dependent) promoter [66-68], was successfully achieved
using NTS-polyplex. However, the promoter was inacti-
vated or the expression was shut down in hemiparkinso-
nian rats presumably due to the depletion in the levels
of Nurr1 in degenerated TH+ neurons [69,70] or due to
the release of Nurr1 protein from nucleus into cyto-
plasm [71]. Even though qRT-PCR experiments in the
SN show the disappearance of hCDNF transcript at day3 after p3xNBRE-hCDNF transfection, ELISA experiments
show the presence of hCDNF protein in both the SN and
striatum even at day 15 after transfection. However,
hCDNF protein levels significantly decreased after day
3 post-transfection. As the half-life of hCDNF remains
unknown, we can suggest that the levels of hCDNF
protein after day 3 post-transfection might correspond
to that protein possibly stored in a cell compartment
and the reduction might be due to the utilization of
protein. This suggestion is supported by the finding
that hCDNF protein levels were almost half when com-
pared with pCR3.1-hCDNF transfection at day 15 after
transfection, both in the SN and in striatum, as CMV
promoter in pCR3.1-hCDNF is still active at day 15
post-transfection (data not shown).
We found basal endogenous levels of rCDNF protein
in rat SN and striatum. This rCDNF expression was
found in the PBP nucleus and in the SNr, but does not
co-localize with TH+ neurons in intact condition,
depicting the published result that CDNF does not co-
localize with TH+ cells [2]. Interestingly, immunofluor-
escence results in intact rat SNc/SNr inter-region shows
the overlay of rCDNF with few TH+ fibers. However,
intranigral transfection in the intact SNc shows the pres-
ence of TH/hCDNF double positive cells because of the
targeted gene transfection of hCDNF. Surprisingly, we
also found induction of rCDNF levels by p3xNBRE-
hCDNF transfection and the levels were 2-fold higher
than that induced by pCR3.1-hCDNF transfection in
hemiparkinsonian rats, and was 4-fold higher than nor-
mal/basal levels. The transfection with pCR3.1-hCDNF
showed no activation of NG2 cells, yet showed GFAP/
CDNF double positive cells, which might be a source for
rCDNF. Whereas the presence of NG2/GFAP/CDNF
triple positive cells in the SNr in L15T15 is more evident
and seems to be more reactive, which is a possible
source for rCDNF levels, in accordance with ELISA re-
sults. Thus, the presence of TH/CDNF double positive
cells in L15T15 may be either due to the presence of
hCDNF protein in TH+ neurons or due to the uptake of
rCDNF by TH+ fibers that was released from NG2-like
astrocytes in the SNr. This entire phenomenon of con-
version of one type of glial cell to another type of glial
cell to produce neurotrophic factor is apparent in the
SNr, and the presence of NG2/GFAP/CDNF triple posi-
tive cells might be an indication of a neuroprotective
effect.
Our observation that the activation or induction of en-
dogenous rCDNF by transient hCDNF transgene might
be either due to homologous recombination or due to
the activation of recombinant activator genes (RAGs).
From our results in intact and L30 conditions, it is clear
that the astrocytes or NG2-like astrocytes are possible
sources of rCDNF. Therefore, one possible mechanism
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transgene, hCDNF, directs the conversion of NG2 progeni-
tor cells towards astrocytes. However, as no published
reports exist, more in-depth research has to be conducted
to identify the mechanism underpinning this phenomenon.
In L15T15, the function and morphology of glial cells
in the SNc is completely opposite with those in the SNr.
p3XNBRE-hCDNF transfection led to the inactivation of
glia cells, decrease of stress markers and absence of
NG2/GFAP/CDNF triple positive cells in the SNc, sug-
gesting the anti-inflammatory role of CDNF in this re-
gion. The reactive glia found in the SNr in L15T15
might only act as a source of rCDNF but might not par-
ticipate in inflammation. CDNF reduced the levels of
TNF-α, IL-1β and IL-6 in tunicamycin-induced astroglial
cell cultures [15], but we observed reduction only in
IL-6 levels in SN in in vivo 6-OHDA induced PD model.
This discrepancy might be explained by the differences
in the models used, but also by the fact that we used
6-OHDA instead of tunicamycin, which is known to
induce very strong ER stress. The protein levels of inflam-
matory cytokines increased in both the SN and striatum
after 6-OHDA injection and hCDNF transfection remain
the same or are slightly increased or decreased depending
on the type of cytokine.
Neurotoxic or neurotrophic effects of TNF-α depends
on the differential localization of its receptors (TNF-α re-
ceptor I or p55 and TNF-α receptor II or p75) in glial and
neuronal cells, their mode of activation, and the down-
stream effectors [72]. Neuroprotective action of TNF-α
(both exogenous or that released by astrocytes) was
proved when TNF-α treated primary astrocytes showed
up-regulation of neural growth factor (NGF), glial cell
line-derived neurotrophic factor (GDNF) and brain-
derived neurotrophic factor (BDNF) [73]. Signals that acti-
vate NF-κB in microglia induce the production of TNF-α.
The released TNF-α binds with TNF-α receptor I on neu-
rons and astrocytes to induce neurotrophic factor (NTF)
production in response to inflammation, thus promoting
neuronal survival [74]. On the other hand, ERK/MAPK
(mitogen-activated protein kinase) pathway also regulates
TNF-α-induced expression of BDNF via CCAAT/enhan-
cer-binding protein β (C/EBPβ) [75]. Besides TNF-α,
IL-1β and IL-6 can also induce activation of C/EBPβ in
astrocytes, leading to NTF production [76,77]. Though
the pathway behind rCDNF up-regulation in astrocytes is
not yet known, available evidence suggests the possible
induction of C/EBPβ. TNF-α can also induce its own pro-
duction by autocrine stimulation, followed by the synthe-
sis of IL-1β and IL-6. Taken together, we propose that
either of those increased levels of cytokines leads to
CDNF, possibly rCDNF, induction by astrocytes.
In addition, increase in IL-1β levels in L15T15 in SN that
can account for the increase of GFAP immunoreactivity. Asthe association of IL-1β and GFAP expression has shown
to be neuroprotective in traumatic injury model [78], we
can expect the same effect in the 6-OHDA PD model.
Moreover, the increased levels of TNF-α and IL-1β can be
beneficial as these cytokines can act as neurotrophic factors
in various PD animal models, thus causing recovery from
neurodegeneration of the nigrostriatal dopaminergic system
[30-32]. IL-6, besides being a pro-inflammatory cytokine,
also acts as an anti-inflammatory cytokine [79-82] and plays
a major role in neuronal differentiation and survival
[83-85]. Considering these, we could propose that IL-6
plays anti-inflammatory and neuroprotective roles in the
6-OHDA dopamine model used in our work as nitrosative
stress and glial markers were absent. Increased striatal
TNF-α might be adaptive, causing its autocrine stimulation,
followed by the synthesis of IL-1β and IL-6 [86]. Based on
that possible adaptive response in the striatum, the differ-
ences in levels of TNF-α, IL-1β and IL-6 in SN and in stri-
atum at L15T15 might be due to the ability of the striatum
to recover from lesion first than the SN. Our results
showed inactivation of NG2 glia and astroglia at L15T15 in
the striatum but not in SN suggesting that striatum is in
next level of recovery from that of SN at that time.
Altogether, the recent findings suggest that the partici-
pation of some unknown mediators, probably hCDNF in
this case, direct these inflammatory cytokines towards
neuroprotection. Reduction of reactive glia and nitrosa-
tive stress markers and stimulation of TNF-α, IL-1β and
IL-6 leading to CDNF production by astrocytes suggest
the anti-inflammatory role of CDNF. It is known that
intrastriatal chronic infusion [13] or adeno-associated
viral hCDNF gene delivery [11] caused neuronal recov-
ery in a rat 6-OHDA model. Our results provide new
insight into the role of CDNF in vivo showing for the
first time that the acute intranigral human CDNF gene
transfection reverses at least some aspects of neuroin-
flammation, possibly as a prelude to its neurotrophic
effect.Conclusions
The present study is the first report demonstrating the
anti-inflammatory effect of CDNF in vivo and in the rat
6-OHDA model of PD. Transient transgenic expression
of hCDNF together with 6-OHDA lesion controls the
activation and conversion of other glial cells, like NG2
and astrocytes, and augments endogenous rCDNF pro-
duction. In the process of neurodegeneration caused by
6-OHDA, stress, including nitrosative stress, is a robust
and first event that is responsible for the apoptotic death
of dopaminergic neurons. We demonstrated that CDNF
is the neurotrophic factor that directly acts at this level
to relieve stress and might prevent the further death of
neurons.
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Additional file 1: Figure S1. Sequential 1-μm optical sections showing
the apparent conversion of a single NG2 cell into an astrocyte cell in L30
SNr. Representative confocal micrographs showing immunoreactivity to
NG2 (green) and GFAP (red). NG2/GFAP is the overlay of the micrographs
in the same row. The scale bars = 20 μm are common for all the
micrographs.
Additional file 2: Figure S2. NG2 cells neither convert into microglia
cells nor produce CDNF in the SNr. Representative merged confocal
micrographs showing immunoreactivity to CDNF (green), OX42 (red), and
NG2 (blue). The triple immune micrographs in the lower row are
expressed individually in first three rows with possible combinations of
double markers to see more details. The headings refer to
mesencephalon slices that were obtained from different rats, intact (A),
with 30-day 6-OHDA lesion, L30 (B), and 15 days of lesion and 15 days of
transfection, L15T15 (C). The scale bars = 20 μm are common for all the
micrographs.
Additional file 3: Figure S3. CDNF immunoreactivity with astrocytes
and/or astrocyte-like NG2 cells in SNr when transfected with
different plasmids. Representative merged confocal micrographs showing
immunoreactivity to CDNF (green), GFAP (red), and NG2 (blue) in the
mesencephalon slices of rats after 15 days of lesion and 15 days of
transfection with pCR3.1-hCDNF (A, L15OT15), with p3xNBRE-EGFP
(B, L15FT15) and with p3xNBRE-hCDNF (C, L15T15); same as shown in
Figure 4, C. The triple immune micrographs in the lower row are
expressed individually in first three rows with possible combinations of
double markers to see more details. Asterisk represents the cell whose
fluorescent markers are individually displayed in the inserts. Graphs
showing the mean fluorescence intensity (MFI) for NG2 (D), GFAP (E)
and CDNF (F). The scale bars = 20 μm is common for all the micrographs.
ns = not significant. ***P < 0.001 when compared with the intact condition.
? = P < 0.001 when compared with L30. One-way ANOVA with
Newman-Keuls post hoc test. n = 4 different rats for each condition.
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